Meriofert Kit (Follicle-Stimulating Hormone, Luteinising Hormone)

FSH binds to receptors on ovarian granulosa cells, stimulating follicle growth and estradiol production. LH binds to receptors on theca cells and mature follicles, triggering ovulation and luteinisation. Together they coordinate the hormonal cascade required for follicular development, oocyte maturation and successful conception.

The dose of Meriofert Kit is individualized. A qualified prescriber determines the amount and frequency based on the patient’s ovarian reserve, treatment protocol and response to monitoring. No fixed regimen is provided in public information.

Meriofert Kit is intended for use before conception and should not be administered during an established pregnancy. Data on safety during breastfeeding are limited, and the product is generally avoided in lactating women unless the prescriber judges the benefit outweighs potential risk.

To order, submit an enquiry on the Meriofert Kit product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Meriofert Kit combines both FSH and LH in a single injection, whereas some alternatives provide only recombinant FSH or separate LH preparations. Compared with urinary‑derived preparations, Meriofert Kit offers a consistent, EU‑sourced composition and is administered subcutaneously, which may improve patient convenience and dosing precision.

Meriofert Kit must be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temperature excursions occur, consult the supplier before use.

The kit is supplied as a sterile lyophilised powder that is reconstituted with the provided diluent. After gentle mixing, the solution is drawn into a syringe and injected subcutaneously, usually into the abdomen or thigh, following the dosing schedule prescribed by the treating physician.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can lead to rapid weight gain, fluid accumulation, thromboembolic events, and, in rare cases, ovarian torsion. Allergic reactions ranging from urticaria to anaphylaxis may also occur and require immediate medical attention.

Meriofert Kit is contraindicated in patients with known hypersensitivity to any component of the product, in established pregnancy, and in individuals with uncontrolled thyroid disease, active ovarian cysts, or severe uncontrolled metabolic disorders. Clinicians should also avoid use in patients with a history of severe OHSS.